193 related articles for article (PubMed ID: 27456759)
1. Development and characterization of a long-acting nanoformulated abacavir prodrug.
Singh D; McMillan J; Hilaire J; Gautam N; Palandri D; Alnouti Y; Gendelman HE; Edagwa B
Nanomedicine (Lond); 2016 Aug; 11(15):1913-27. PubMed ID: 27456759
[TBL] [Abstract][Full Text] [Related]
2. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.
Zhou T; Su H; Dash P; Lin Z; Dyavar Shetty BL; Kocher T; Szlachetka A; Lamberty B; Fox HS; Poluektova L; Gorantla S; McMillan J; Gautam N; Mosley RL; Alnouti Y; Edagwa B; Gendelman HE
Biomaterials; 2018 Jan; 151():53-65. PubMed ID: 29059541
[TBL] [Abstract][Full Text] [Related]
3. Creation of a Long-Acting Nanoformulated 2',3'-Dideoxy-3'-Thiacytidine.
Guo D; Zhou T; Araínga M; Palandri D; Gautam N; Bronich T; Alnouti Y; McMillan J; Edagwa B; Gendelman HE
J Acquir Immune Defic Syndr; 2017 Mar; 74(3):e75-e83. PubMed ID: 27559685
[TBL] [Abstract][Full Text] [Related]
4. Creation of a long-acting rilpivirine prodrug nanoformulation.
Hilaire JR; Bade AN; Sillman B; Gautam N; Herskovitz J; Dyavar Shetty BL; Wojtkiewicz MS; Szlachetka A; Lamberty BG; Sravanam S; Fox HS; Alnouti Y; Dash PK; McMillan JM; Edagwa BJ; Gendelman HE
J Control Release; 2019 Oct; 311-312():201-211. PubMed ID: 31491432
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation.
Ibrahim IM; Bade AN; Lin Z; Soni D; Wojtkiewicz M; Dyavar Shetty BL; Gautam N; McMillan JM; Alnouti Y; Edagwa BJ; Gendelman HE
Int J Nanomedicine; 2019; 14():6231-6247. PubMed ID: 31496683
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.
Puligujja P; Balkundi SS; Kendrick LM; Baldridge HM; Hilaire JR; Bade AN; Dash PK; Zhang G; Poluektova LY; Gorantla S; Liu XM; Ying T; Feng Y; Wang Y; Dimitrov DS; McMillan JM; Gendelman HE
Biomaterials; 2015 Feb; 41():141-50. PubMed ID: 25522973
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques.
McMillan J; Szlachetka A; Slack L; Sillman B; Lamberty B; Morsey B; Callen S; Gautam N; Alnouti Y; Edagwa B; Gendelman HE; Fox HS
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061742
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques.
McMillan J; Szlachetka A; Zhou T; Morsey B; Lamberty B; Callen S; Gautam N; Alnouti Y; Edagwa B; Gendelman HE; Fox HS
AIDS; 2019 Mar; 33(3):585-588. PubMed ID: 30289818
[TBL] [Abstract][Full Text] [Related]
9. A long acting nanoformulated lamivudine ProTide.
Smith N; Bade AN; Soni D; Gautam N; Alnouti Y; Herskovitz J; Ibrahim IM; Wojtkiewicz MS; Dyavar Shetty BL; McMillan J; Gendelman HE; Edagwa B
Biomaterials; 2019 Dec; 223():119476. PubMed ID: 31525692
[TBL] [Abstract][Full Text] [Related]
10. Modulating cellular autophagy for controlled antiretroviral drug release.
Thomas MB; Gnanadhas DP; Dash PK; Machhi J; Lin Z; McMillan J; Edagwa B; Gelbard H; Gendelman HE; Gorantla S
Nanomedicine (Lond); 2018 Sep; 13(17):2139-2154. PubMed ID: 30129397
[TBL] [Abstract][Full Text] [Related]
11. Injectable long-acting human immunodeficiency virus antiretroviral prodrugs with improved pharmacokinetic profiles.
Krovi SA; Gallovic MD; Keller AM; Bhat M; Tiet P; Chen N; Collier MA; Gurysh EG; Pino EN; Johnson MM; Shamim Hasan Zahid M; Cottrell ML; Pirone JR; Kashuba AD; Kwiek JJ; Bachelder EM; Ainslie KM
Int J Pharm; 2018 Dec; 552(1-2):371-377. PubMed ID: 30308272
[TBL] [Abstract][Full Text] [Related]
12. Improved antiviral activity of the aryloxymethoxyalaninyl phosphoramidate (APA) prodrug of abacavir (ABC) is due to the formation of markedly increased carbovir 5'-triphosphate metabolite levels.
Balzarini J; Aquaro S; Hassan-Abdallah A; Daluge SM; Perno CF; McGuigan C
FEBS Lett; 2004 Aug; 573(1-3):38-44. PubMed ID: 15327972
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice.
Puligujja P; Araínga M; Dash P; Palandri D; Mosley RL; Gorantla S; Poluektova L; McMillan J; Gendelman HE
Antiviral Res; 2015 Aug; 120():85-8. PubMed ID: 26026666
[TBL] [Abstract][Full Text] [Related]
14. Novel elvitegravir nanoformulation for drug delivery across the blood-brain barrier to achieve HIV-1 suppression in the CNS macrophages.
Gong Y; Chowdhury P; Nagesh PKB; Rahman MA; Zhi K; Yallapu MM; Kumar S
Sci Rep; 2020 Mar; 10(1):3835. PubMed ID: 32123217
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of a long acting nanoformulated emtricitabine ProTide.
Soni D; Bade AN; Gautam N; Herskovitz J; Ibrahim IM; Smith N; Wojtkiewicz MS; Dyavar Shetty BL; Alnouti Y; McMillan J; Gendelman HE; Edagwa BJ
Biomaterials; 2019 Nov; 222():119441. PubMed ID: 31472458
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Characterization of Long-Acting Darunavir Prodrugs.
Banoub MG; Bade AN; Lin Z; Cobb D; Gautam N; Dyavar Shetty BL; Wojtkiewicz M; Alnouti Y; McMillan J; Gendelman HE; Edagwa B
Mol Pharm; 2020 Jan; 17(1):155-166. PubMed ID: 31742407
[TBL] [Abstract][Full Text] [Related]
17. Tools for eradicating HIV in the brain: prodrug dimeric inhibitors of P-gp.
Chmielewski J; Hrycyna C
Ther Deliv; 2012 Jun; 3(6):689-92. PubMed ID: 22838065
[TBL] [Abstract][Full Text] [Related]
18. Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages.
Araínga M; Guo D; Wiederin J; Ciborowski P; McMillan J; Gendelman HE
Retrovirology; 2015 Jan; 12():5. PubMed ID: 25608975
[TBL] [Abstract][Full Text] [Related]
19. Hydroxy fatty acids for the delivery of dideoxynucleosides as anti-HIV agents.
Gangadhara KL; Lescrinier E; Pannecouque C; Herdewijn P
Bioorg Med Chem Lett; 2014 Feb; 24(3):817-20. PubMed ID: 24411122
[TBL] [Abstract][Full Text] [Related]
20. Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection.
Anderson AM; Bartlett JA
Expert Rev Anti Infect Ther; 2005 Dec; 3(6):871-83. PubMed ID: 16307500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
